Real-world effectiveness of allergen immunotherapy

Details currently being finalised

Lead Investigator:
Claus Bachert
Research Team:
Status: Proposed Study, Seeking Funding
Support:
Registration:
Documents and Publications:
Protocol
Abstracts
Presentations
Final Publications
Additional Material

Device switching (e.g. from ICS/LABA DPI to pMDI)(s) to FP/FOR pMDIs (Transfform)

The objective of this study is to evaluate acceptance of FOR/ICS pMDI by assessing ‘switch success’ of changing asthma patients from FP/SAL DiskusTM to FP/FOR or other ICS/LABA pMDI inhalers in a real-world population in Korea.
Lead Investigator:
Job van Boven
Research Team:
Status: Proposed Study, Seeking Funding
Support:
Registration:
Documents and Publications
Protocol
Abstracts
Presentations
Final Publications
Additional Material

Evaluate the implications of single versus multiple device use on implementation of triple therapy in eligible patients with COPD managed in routine care

The primary objective of this study is to evaluate whether a single fixed dose combination (FDC) triple therapy (inhaled corticosteroid & dual bronchodilation) treatment regimen in patients with COPD is associated with better real-life clinical outcomes than use of “free” triple regimens. The study will also evaluate the association between frequency of dosing regimen (e.g. once daily versus twice daily) and clinical outcomes in the real-world management of patients with COPD. Lead Investigator:
Alberto Papi
Research Team:
David Price, Claus Vogelmeier, Marc Miravitlles, Nicolas Roche. Status: Proposed Study, Seeking Funding
Support:
Registration:
Documents and Publications
Protocol
Abstracts
Presentations
Final Publications
Additional Material

Implementation of national recommendations for community acquired pneumonia in routine care – Recommendations by the National Institute for Health and Care Excellence in the UK

 

This study aims to evaluate the extent to which the BTS/NICE clinical standards for the diagnosis and management of CAP in adults are currently implemented in UK primary care, specifically evaluating:
(i) The recording of the CRB65 at the time of CAP diagnosis in primary care patients
(ii) Evaluate antibiotic prescribing patterns at the time of CAP diagnosis in primary care.
The objective of the work is to improve understanding current clinical practice behaviours with a view to assessing the feasibility and scale of practice change required to implement the BTS/NICE recommendations diagnosis and management of CAP moving forward.
Lead Investigator:
Chris Winchester: Chief Executive Officer of Oxford Pharmagenesis, Oxford, UK
Research Team:
David Price, Professor of Primary Care Respiratory Medicine, University of Aberdeen, Aberdeen, UK; Owner of Optimum Patient Care Ltd and REG Chairman
Alison Chisholm: Chief Scientific Officer of REG, Cambridge, UK
Anjan Nibber: Researcher, Research in Real Life on behalf of REG, Cambridge, UK
Status: Active Study
Support:
Registration:
Documents and Publications
Protocol
Abstracts
Presentations
Final Publications
Additional Material

Utilise routine care data to identify the optimum duration of antibiotics for respiratory infections

The aim of the proposed study is to characterise patterns in the duration of antibiotic prescribing for lower respiratory tract infections (LRTI) and to evaluate the repeat prescription rate (and differences therein) associated with commonly prescribed antibiotic course duration in the UK (i.e. 5-, 7-, 10-, and 14-days). Specific analyses will be undertaken for individuals with COPD and for individuals with asthma.
Lead Investigator:
John Blakey: Senior Lecturer, Liverpool School of Tropical Medicine, Honorary Consultant, Aintree University Hospital, UK
Research Team:
Marie Stolbrink: NIHR Academic Clinical Fellow, Aintree University Hospital and University of Liverpool, UK
Dan Wootton: Clinical Lecturer, Institute of Infection and Global Health, University of Liverpool, UK
Laura Bonnett: NIHR Postdoctoral Fellow, University of Liverpool, UK
David Price: Professor of Primary Care Respiratory Medicine, University of Aberdeen, Aberdeen, UK; Owner of Optimum Patient Care Ltd and Chairman of the Respiratory Effectiveness Group, Cambridge, UK
Victoria Carter: General Manager of Optimum Patient Care, Cambridge, UK
Alison Chisholm: Chief Scientific Officer of the Respiratory Effectiveness Group, Cambridge, UK
Nikos Papadopoulos: Professor of Allergy and Paediatric Allergy, Manchester University and Royal Manchester Children’s Hospital, UK
Clare Murray: Senior Lecturer, Manchester University Centre for Respiratory Medicine and Allergy, Consultant in Respiratory Paediatrics, University Hospital of South Manchester, UK
Status: Proposed Study, Seeking Funding
Support:
Registration:
Documents and Publications
Protocol
Abstracts
Presentations
Final Publications
Additional Material

Implications of steroid tailoring on treatment outcomes in patients with COPD managed in routine care

The aim of the study is to evaluate the effect of ICS withdrawal (evaluated as dose reduction and cessation) on real-world clinical outcomes in patients with confirmed COPD who are adherent to ICS therapy (medication possession ratio [MPR] ≥70%).
Lead Investigator:
Dirkje S. Postma: University Medical Center Groningen, Groningen, The Netherlands
Research Team:
Working Group Lead – Marc Miravitlles: Pneumology Department, Vall d’ Hebron University Hospital, Barcelona, Spain
David Price: Professor of Primary Care Respiratory Medicine, University of Aberdeen, Aberdeen, UK; Owner of Optimum Patient Care Ltd
Helgo Magnussen: Pulmonary Research Institute at Lung Clinic Grosshansdorf, Germany
Dermot Ryan: Honorary Fellow at the University of Edinburgh; Consultant at Optimum Patient Care Ltd, Cambridge, UK
Ronald Dandurand: Montreal Chest Institute & Meakins-Christie Laboratories, McGill University Health Centre, Montreal, QC, Canada
Jens Dollerup: Dollerup Medical Consultancy, Copenhagen, Denmark
Alberto Papi: S. Anna University Hospital, Ferrara, Italy
Nicolas Roche: University of Paris Descartes, Paris, France
Jennifer Quint: Imperial College, London, UK
Therese Lapperre: Singapore General Hospital, Singapore, Singapore
Caroline Gouder: Mater Dei Hospital, Valletta, Malta
Richard Costello: Royal College of Surgeons, Dublin, Ireland
Juan José Soler-Cataluña: Pneumology Department, Hospital Arnau de Vilanova, Valencia, Spain and CIBER de Enfermedades Respiratorias (CIBERES)
Faisal Yunus: Department of Pulmonology and Respiratory Medicine, Universitas Indonesia (FMUI), Jakarta, Indonesia
Bernardino Alcazar Navarrete: Respiratory Department, Hospital de Alta Resolucion, Granada, Spain
David Halpin: Department of Respiratory Medicine, Royal Devon & Exeter Hospital, Exeter
Akio Niimi: Department of Respiratory Medicine, Kyoto University Graduate School of Medicine
Alison Chisholm: Chief Scientific Officer of the Respiratory Effectiveness Group, Cambridge, UK
Status: Proposed Study, Seeking Funding
Support:
Registration:
Documents and Publications
Protocol
Abstracts
Presentations
Final Publications
Additional Material

Evaluate the real-world prevalence of comorbidities in patients with COPD and their impact on COPD symptoms and quality of life

Chronic obstructive pulmonary disease (COPD) is associated with comorbidities that increase in number and severity with age and are more prevalent among deprived social groups. Little is yet known about prevalence of comorbidities with COPD and its impact in quality of life in primary care populations. Increasing this knowledge is relevant for the development of better intervention strategies and for informing the reframing of clinical guidelines in primary care.
This study aims to enhance knowledge in terms of prevalence of comorbidities in COPD patients and their impact on the quality of life and on COPD symptoms in primary care patients. This study will address the following research questions:

1. What is the prevalence of comorbidities in COPD patients in primary care?
2. What is the impact of one or more comorbidities on the quality of life and on COPD symptoms?
3. What is the impact of one or more comorbidities on the exacerbations in COPD?

Lead Investigators:
Björn Ställberg
Pedro M Teixeira
Research Team:
Status: Active Study
Support: IPCRG
Registration:
Documents and Publications
Protocol
Abstracts
Presentations
Final Publications
Additional Material

Evaluate the prevalence of inappropriate SABA (excess) and LABA (monotherapy) prescribing in patients with asthma

The aim to the study is to compare asthma management between patients in the United Kingdom (UK) and in France, more particularly regarding at-risk treatment patterns.
Lead Investigator:
Eric van Ganse
David Price
Dermot Ryan
Research Team:
Status: Active Study
Support:
Registration:
Documents and Publications
Protocol
Abstracts
Presentations
Final Publications
Additional Material

Characterisation of current asthma management practice and asthma-related morbidity

Questionnaire-based surveys report that uncontrolled asthma is common in Europe, and associated with high healthcare costs. The relationship between treatment step control are less well described. The aim of the study was to quantify the asthma burden within routine primary care in the UK, specifically the distribution of asthma control across guideline-recommended management steps and the association between patients’ control and smoking status.
Patients were retrospectively identified using the Optimum Patient Care Research Database and prospectively followed-up for at least 1-year. Patients’ routine clinical data and self reports were used to assess GINA control status; clinical records were used to categorise current treatment by GINA management steps and patients’ smoking status.
Lead Investigator:
Anjan Nibber, RiRL
Research Team:
• Mike Thomas
• Vicky Thomas
• Wim van Aalderen
• Eugene Bleecker
• Jonathan Campbell
• Nicolas Roche
• John Haughney
• Eric Van Ganse
• Hye-Yun Park
• Chin Kook Rhee
• Derek Skinner
• Alison Chisholm
• Job FM van Boven
• Joan B. Soriano
• David Price
Status: Active Study
Support: Teva, Research in Real Life
Registration: ENCEPP – EU PAS Register Number EUPAS8740
Documents and Publications
Protocol
Abstracts
Journal of Thoracic Disease: REG 2016 Summit Abstracts
Presentations
Final Publications
Additional Material

Implications of ICS prescription duration on asthma outcomes

The study aims at assessing the relation between prescription patterns (unchanged vs increased script duration) and (i) cumulative time covered (MPR, medication possession ratio) and (ii) clinical outcomes over a one-year outcome period, in patients receiving ICS with any script duration during the baseline year.

Lead Investigator:

Lead Investigator

Professor David Price, Professor of Primary Care Respiratory Medicine and RiRL Director

Research Team:

  • Nicolas Roche
  • Dirkje Postma
  • Richard Martin
  • Eliot Israel
  • Gene Colice
  • Rupert Jones
  • Catherine Hutton
  • Dr Arjun Jain
  • Vicky Thomas
  • Derek Skinner

Status: Active Study

Support:

Registration:

Documents and Publications

Protocol

Abstracts

Presentations

Final Publications

Additional Material